Diligence memo · auto-generated · as of July 3, 2026
Pacific Biosciences Of California, Inc.
Pacific Biosciences Of California, Inc. looks over-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Pacific Biosciences Of California, Inc. operates in Biotech / Pharma, based in MENLO PARK.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Pacific Biosciences Of California, Inc. has raised $190M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $85M on 2023-08-02.
Most recent recorded round closed around 2023-10-04.
Valuation (modeled)modeled
Provath models Pacific Biosciences Of California, Inc. at approximately $982M (range $269M–$1.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.95× the median modeled value of Series C Biotech / Pharma companies in 2022–2024 (8 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 64 months.
Last raise 2.7 yr ago; this sector typically re-raises about every 15 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 1.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 98% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 95% of those peers.
Closest niche peers: Sherlock Biosciences, Inc., Sudo Biosciences, Inc., Elephas Biosciences Corp, NOLA PharmaHoldings, LLC, Belenos Biosciences, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.